| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $171,860,510 ) (Continued on the next page) |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R00CA266921 | SESORRS endoscopy for the staging and evaluation of colorectal cancer | 000 | 4 | NIH | 12/23/2024 | $170,893 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AI179839 | High-throughput single-cell RNA sequencing of bacteria to uncover cell states involved in pathogenesis | 000 | 2 | NIH | 5/6/2025 | $813,272 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U24HG004059 | Bioconductor: An Open-Source, Open-Development Computing Resource for Genomics | 000 | 21 | NIH | 3/27/2025 | $922,833 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA274276 | Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity | 001 | 4 | NIH | 8/26/2025 | $1,037,023 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U24HG011451 | Generating a full-length reference transcriptome for human protein-coding genes | 001 | 4 | NIH | 9/8/2025 | $640,208 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U24HG004059 | Bioconductor: An Open-Source, Open-Development Computing Resource for Genomics | 001 | 21 | NIH | 4/25/2025 | $102,536 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R35CA293978 | Mechanisms Driving the Rapid Evolution of Cancer Genomes | 000 | 2 | NIH | 8/4/2025 | $1,068,000 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R50CA251956 | Single cell investigation of co-evolution in cancer cells and host cell immune microenvironment | 000 | 6 | NIH | 7/25/2025 | $327,006 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA269990 | Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer | 000 | 3 | NIH | 11/6/2024 | $420,355 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA269990 | Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer | 001 | 3 | NIH | 6/3/2025 | $46,705 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U24CA224331 | Cancer Immune Monitoring and Analysis Center | 000 | 4 | NIH | 8/28/2025 | $1,934,873 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R25CA291637 | The Young Empowered Scientists for ContinUed Research Engagement (YES for CURE) Program at the Dana-Farber/Harvard Cancer Center (DF/HCC) | 000 | 2 | NIH | 7/17/2025 | $388,712 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA255245 | Targeting vulnerabilities of PPM1D-mutant gliomas | 001 | 5 | NIH | 6/4/2025 | $40,361 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA255245 | Targeting vulnerabilities of PPM1D-mutant gliomas | 000 | 5 | NIH | 1/13/2025 | $363,246 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01LM014775 | Computational methods for multiplex image analysis of the tumor microenvironment | 000 | 1 | NIH | 9/1/2025 | $1,602,000 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA300921 | Immune Evasion through HLA-E in Diffuse Large B-Cell Lymphoma: Defining Its Regulation and Cellular Interactions | 000 | 1 | NIH | 9/2/2025 | $241,884 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32GM154489 | Expanding the understanding of tRNA lifecycle under cellular stress | 000 | 1 | NIH | 8/29/2025 | $78,040 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32GM154489 | Expanding the understanding of tRNA lifecycle under cellular stress | 001 | 1 | NIH | 8/29/2025 | $0 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32HL182347 | Examining the role of adenosine-sensing by macrophages in obesity-induced cardiac inflammation | 000 | 1 | NIH | 9/4/2025 | $75,052 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32HL182347 | Examining the role of adenosine-sensing by macrophages in obesity-induced cardiac inflammation | 001 | 1 | NIH | 9/4/2025 | $0 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA269285 | Cyclin C-CDK8/19 kinases in development and in cancer | 001 | 4 | NIH | 5/28/2025 | $52,596 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA269285 | Cyclin C-CDK8/19 kinases in development and in cancer | 000 | 4 | NIH | 3/4/2025 | $473,373 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA286537 | Mechanism and functional consequences of dietary lipids in lineage specification and tumor growth in oncohistone gliomas | 001 | 2 | NIH | 5/22/2025 | $70,246 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA300495 | Dissecting the impact of tumor-immune spatial interactions in mismatch-repair stratified colorectal cancers | 000 | 1 | NIH | 8/1/2025 | $170,641 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA286537 | Mechanism and functional consequences of dietary lipids in lineage specification and tumor growth in oncohistone gliomas | 000 | 2 | NIH | 3/4/2025 | $632,213 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA300498 | Engineered Living Materials as Programmable Therapeutic Implants for Pancreatic Cancer | 000 | 1 | NIH | 8/25/2025 | $137,995 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HG014175 | Calling germline and mosaic variants from long genomic and RNA-seq reads | 000 | 1 | NIH | 8/15/2025 | $501,618 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA284254 | Defining Therapeutically Targetable Regulators of Tumor-Intrinsic Immune Suppression in Glioblastoma | 000 | 3 | NIH | 2/13/2025 | $99,216 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA288234 | Investigating Interactions Between Radiation and Antibody-Drug Conjugates in Bladder Cancer | 001 | 2 | NIH | 5/22/2025 | $24,678 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA288234 | Investigating Interactions Between Radiation and Antibody-Drug Conjugates in Bladder Cancer | 000 | 2 | NIH | 2/13/2025 | $222,106 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA306146 | Elucidating the role of PATZ1 in MYCN-amplified neuroblastoma | 001 | 1 | NIH | 7/28/2025 | $0 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA306146 | Elucidating the role of PATZ1 in MYCN-amplified neuroblastoma | 000 | 1 | NIH | 7/28/2025 | $78,040 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U10CA180794 | ECOG-ACRIN Network Group Statistics and Data Management Center | 001 | 11 | NIH | 7/16/2025 | $3,099,295 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U10CA180794 | ECOG-ACRIN Network Group Statistics and Data Management Center | 000 | 11 | NIH | 2/28/2025 | $4,683,890 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DE034386 | Dissecting CCL5 contribution to antigen specific T cell responses in head and neck cancers | 000 | 1 | NIH | 8/21/2025 | $3,742,682 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R00CA286805 | Dissecting the Role of Germline Genetics in RAS-Driven Cancers | 000 | 3 | NIH | 8/14/2025 | $248,999 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R00CA286805 | Dissecting the Role of Germline Genetics in RAS-Driven Cancers | 001 | 3 | NIH | 9/22/2025 | -$248,999 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R00CA286805 | Dissecting the Role of Germline Genetics in RAS-Driven Cancers | 001 | 3 | NIH | 9/22/2025 | $248,999 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA258688 | Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer | 001 | 5 | NIH | 5/22/2025 | $40,717 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA258688 | Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer | 000 | 5 | NIH | 3/13/2025 | $366,458 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA284750 | Investigating IGF2BP1 as a novel Therapeutic Target for Ewing Sarcoma | 002 | 2 | NIH | 8/6/2025 | -$54,193 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA284750 | Investigating IGF2BP1 as a novel Therapeutic Target for Ewing Sarcoma | 001 | 2 | NIH | 5/29/2025 | $1,236 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA284750 | Investigating IGF2BP1 as a novel Therapeutic Target for Ewing Sarcoma | 000 | 2 | NIH | 3/12/2025 | $74,284 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279391 | Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | 001 | 2 | NIH | 5/22/2025 | $70,351 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA248393 | Development of microRNA (miR)-based cell-targeted polymeric nanoparticles for myeloma therapy | 000 | 5 | NIH | 3/12/2025 | $495,790 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279391 | Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | 000 | 2 | NIH | 2/13/2025 | $633,159 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA298459 | Interrogating the role of IFNgamma in promoting metastasis and immune evasion of triple negative breast cancer | 000 | 1 | NIH | 7/15/2025 | $75,520 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA298459 | Interrogating the role of IFNgamma in promoting metastasis and immune evasion of triple negative breast cancer | 001 | 1 | NIH | 7/15/2025 | $0 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA248393 | Development of microRNA (miR)-based cell-targeted polymeric nanoparticles for myeloma therapy | 001 | 5 | NIH | 5/22/2025 | $55,087 |
|
